Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | CPT1A | P50416 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 2/20 | 0.31 |
| ▸ | RHOA | P61586 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.30 |
| ▸ | ACP1 | P24666 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296784 | 0.93 | HCRTR1 (0.31) | — | |
| SCHEMBL13705298 | 0.93 | PDE4B (0.32) | HTR7FAAHOPRD1 | |
| SCHEMBL4286204 | 0.92 | CHKA (0.33) | OPRD1 | |
| SCHEMBL4287181 | 0.89 | HCRTR1 (0.37) | CPT2CPT1AOPRD1 | |
| SCHEMBL4281719 | 0.89 | ACP1 (0.36) | HTR7CPT2CPT1ACASRACP1 | |
| SCHEMBL4293922 | 0.87 | NOS2 (0.32) | — | |
| SCHEMBL4282753 | 0.86 | HCRTR1 (0.38) | CPT2CPT1AOPRD1 | |
| SCHEMBL4290990 | 0.86 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL4287523 | 0.86 | MAPT (0.35) | — | |
| SCHEMBL4281526 | 0.86 | HCRTR1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HTR7 1874/4885CPT2 4179/4885CPT1A 1277/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HTR7 1874/4885CPT2 4179/4885CPT1A 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.